HYPERION DEFI, INC. quarterly report, Q1 FY2024

Business Context and Reporting Period

Filing identity: The supplied metadata names HYPERION DEFI, INC., but the filing itself is Eyenovia, Inc. (Nasdaq: EYEN). Confirm the issuer and filing before relying on this summary.

This unaudited Form 10-Q covers the three months ended March 31, 2024. Eyenovia is an ophthalmic pharmaceutical technology company developing products using its Optejet delivery platform. Its products include Mydcombi, which it has begun commercializing, and FDA-approved clobetasol ophthalmic suspension; it is also developing MicroPine for progressive myopia and other programs.

Financial Performance and Position

Revenue was immaterial and fully offset by cost of revenue, producing no gross profit. Management expects flat gross margins in the early Mydcombi commercialization phase, including until production can scale and the second-generation Optejet is rolled out. The filing reports a $198,034 inventory write-down.

Cash and cash equivalents were $7.98 million at March 31, down from $14.85 million at December 31, 2023. Working capital was a deficit of $2.01 million, compared with positive working capital of $11.18 million at year-end. Total assets were $26.18 million, total liabilities $24.36 million, and stockholders’ equity $1.82 million. Gross notes payable were $16.08 million; the balance sheet also reports lease liabilities, with $1.72 million present value outstanding.

Financing activities provided $3.13 million, primarily from approximately $3.19 million net proceeds under the at-the-market (ATM) offering. The company had an accumulated deficit of $156.41 million and no recurring revenue.

Material Changes Versus Prior Period

• Net loss increased approximately 90% year over year; operating cash use rose approximately 42%.
• R&D expense increased about 76%, driven by personnel, supplies and materials, clinical and non-clinical work, and depreciation. G&A expense increased about 31%.
• In January, Eyenovia agreed to reacquire MicroPine rights from Bausch + Lomb, recording a $2.0 million operating expense. Rights and certain study assets transferred April 11; the company issued Bausch + Lomb 2,299,397 shares valued at $3.0 million on May 3. The agreement also provides for a low single-digit royalty on future U.S. and Canadian net sales.
• FDA approval of the clobetasol product and acceptance of the regulatory transfer triggered $4.0 million in development milestone obligations, recorded as an intangible asset and accrual. The first $2.0 million milestone was paid after quarter-end with $1.0 million cash and $1.0 million in shares; the second $2.0 million is payable at a future contractual trigger.
• Common shares outstanding increased from 45.55 million at year-end to 47.39 million at March 31, including 1.83 million shares sold through the ATM.

Outlook, Risks, and Unusual Items

Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least one year from issuance of the financial statements. It expects continued operating cash outflows and increased R&D and G&A costs. Additional capital or licensing/business development transactions may be required; absent sufficient funding or revenue, the company may curtail R&D and reduce costs. No specific financial guidance or quantified revenue forecast is provided.

• After quarter-end, the company raised approximately $2.0 million gross in a registered direct offering of 3,223,726 shares at $0.6204 per share. It also reported approximately $317,000 net ATM proceeds from 347,794 shares, then suspended and terminated the then-current ATM prospectus supplement on April 8.
• A post-quarter agreement with Bausch + Lomb set the defective clinical supply settlement at approximately $0.5 million; Eyenovia also expects approximately $0.25 million from Bausch + Lomb for a vendor holdback liability. Eyenovia purchased an additional $0.5 million of clinical supplies in April.
• Contractual commitments disclosed for the next 12 months include $5.7 million of March 31 accounts payable and accrued liabilities, $0.6 million of lease commitments, and $8.8 million of gross note and convertible-note payments if not previously converted. A further $1.1 million of lease payments and $7.3 million of gross debt payments are due thereafter.
• Management identified potential exposure to higher manufacturing input costs related to geopolitical conflicts and sanctions. The filing reports no material legal proceedings and no material changes to the risk factors in the latest Form 10-K.
• Management concluded disclosure controls were effective at a reasonable assurance level as of March 31, 2024; it reported no material change in internal control over financial reporting during the quarter.

Important Facts for Investors to Verify

1. Confirm the issuer identity: the request metadata says HYPERION DEFI, INC., while the filing names Eyenovia, Inc.
2. Assess financing needs and runway in light of $7.98 million quarter-end cash, $9.89 million quarterly operating cash use, negative working capital, and the going-concern warning; incorporate the post-quarter financing and share issuance.
3. Review debt terms, maturities, conversion provisions, and the contractual commitment schedule, including the $8.8 million of gross debt payments identified for the next 12 months.
4. Track execution and costs of the Bausch + Lomb rights reacquisition, the CHAPERONE study and planned late-2024 interim analysis, and commercialization of Mydcombi and clobetasol.
5. Reconcile the MD&A narrative that describes Q1 R&D as $3.9 million with the financial statements and MD&A expense table, both of which report $4.43 million.
6. Verify future milestone payments, sales-based royalties, and the impact of further equity issuance and dilution.